60 DEGREES PHARMACEUTICALS, INC. Amortization of Intangible Assets
60 DEGREES PHARMACEUTICALS, INC. (SXTP) reported Amortization of Intangible Assets of $13.86 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-14
- 60 DEGREES PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2026-06-30 was $13.86K, a 32.73% increase year-over-year.
- 60 DEGREES PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2026-03-31 was $9.16K, a 9.28% decline year-over-year.
- 60 DEGREES PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2025-12-31 was $8.40K, a 20.00% decline year-over-year.
- 60 DEGREES PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2025-09-30 was $10.61K, a 2.71% increase year-over-year.
- 60 DEGREES PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2025 was $39.55K, a 2.72% increase from fiscal 2024.
- 60 DEGREES PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2024 was $38.50K, a 32.05% increase from fiscal 2023.
- 60 DEGREES PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2023 was $29.16K, a 469.70% increase from fiscal 2022.
- 60 DEGREES PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2022 was $5.12K.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.86K 10-Q · filed 2026-08-14 | $23.02K 10-Q · filed 2026-08-14 | $31.42K derived: sum of 3 quarters · filed 2026-08-14 | $42.03K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $9.16K 10-Q · filed 2026-05-15 | $17.56K derived: sum of 2 quarters · filed 2026-05-15 | $28.17K derived: sum of 3 quarters · filed 2026-05-15 | $38.61K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $8.40K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $19.00K derived: sum of 2 quarters · filed 2026-03-30 | $29.45K derived: sum of 3 quarters · filed 2026-08-14 | $39.55K 10-K · filed 2026-03-30 |
| 2025-09-30 | $10.61K 10-Q · filed 2025-11-13 | $21.05K derived: sum of 2 quarters · filed 2026-08-14 | $31.15K 10-Q · filed 2025-11-13 | $41.65K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $10.44K 10-Q · filed 2026-08-14 | $20.55K 10-Q · filed 2026-08-14 | $31.04K derived: sum of 3 quarters · filed 2026-08-14 | $41.37K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $10.10K 10-Q · filed 2026-05-15 | $20.60K derived: sum of 2 quarters · filed 2026-05-15 | $30.93K derived: sum of 3 quarters · filed 2026-05-15 | $40.40K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $10.50K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $20.82K derived: sum of 2 quarters · filed 2026-03-30 | $30.30K derived: sum of 3 quarters · filed 2026-03-30 | $38.50K 10-K · filed 2026-03-30 |
| 2024-09-30 | $10.32K 10-Q · filed 2025-11-13 | $19.80K derived: sum of 2 quarters · filed 2025-11-13 | $28.00K 10-Q · filed 2025-11-13 | $36.55K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $9.47K 10-Q · filed 2025-08-13 | $17.68K 10-Q · filed 2025-08-13 | $26.23K derived: sum of 3 quarters · filed 2025-08-13 | $33.64K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $8.21K 10-Q · filed 2025-05-15 | $16.76K derived: sum of 2 quarters · filed 2025-05-15 | $24.17K derived: sum of 3 quarters · filed 2025-05-15 | $30.19K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $8.55K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $15.96K derived: sum of 2 quarters · filed 2025-03-27 | $21.98K derived: sum of 3 quarters · filed 2025-03-27 | $29.16K 10-K · filed 2025-03-27 |
| 2023-09-30 | $7.41K 10-Q · filed 2024-11-14 | $13.43K derived: sum of 2 quarters · filed 2024-11-14 | $20.61K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $6.02K 10-Q · filed 2024-08-14 | $13.19K 10-Q · filed 2024-08-14 | ||
| 2022-12-31 | $2.33K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $4.17K derived: sum of 2 quarters · filed 2024-04-01 | $5.12K derived: sum of 3 quarters · filed 2024-04-01 | $5.12K 10-K · filed 2024-04-01 |
| 2022-09-30 | $1.83K 10-Q · filed 2023-11-20 | $2.78K derived: sum of 2 quarters · filed 2023-11-20 | $2.78K 10-Q · filed 2023-11-20 | |
| 2022-06-30 | $952.00 10-Q · filed 2023-08-25 | $1.96K 10-Q · filed 2023-08-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 |